UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,056	03/16/2007	Katherine S. Bowdish	ALEX-P01-112	8249
28120 ROPES & GRA	7590 02/16/201 XY LLP	EXAMINER		
IPRM - Floor 43 PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	
			NOTIFICATION DATE	DELIVERY MODE
			02/16/2011	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatentMail@ropesgray.com USPatentMail2@ropesgray.com

	Application No.	Applicant(s)	
	10/583,056	BOWDISH ET AL.	
Office Action Summary	Examiner	Art Unit	
	G. R. Ewoldt, Ph.D.	1644	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION (136(a)). In no event, however, may a repart will apply and will expire SIX (6) MONTILE, cause the application to become ABA	ATION.  ly be timely filed  IS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).	
Status			
1) ■ Responsive to communication(s) filed on <u>03 L</u> 2a) ■ This action is <b>FINAL</b> . 2b) ■ This action for allowed closed in accordance with the practice under	s action is non-final. ance except for formal matte	·	
Disposition of Claims			
4)	awn from consideration.  2 is/are rejected.	n.	
Application Papers			
9) The specification is objected to by the Examina  10) The drawing(s) filed on is/are: a) accomposed as a composition and a composition and a composition to the separate and a composition and a composition and a composition are contact and a composition and a composition are contact and a contact	cepted or b) objected to be drawing(s) be held in abeyanction is required if the drawing(s	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. Its have been received in Appority documents have been re Bu (PCT Rule 17.2(a)).	olication No eceived in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ☐ Interview Su Paper No(s)	mmary (PTO-413) Mail Date	
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>8/12/10</u> .		ormal Patent Application	

Application/Control Number: 10/583,056

Art Unit: 1644

## DETAILED ACTION

Page 2

- 1. A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed 10/04/10 in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's amendment and remarks filed 10/04/10 have been entered. Applicant's IDS's filed 8/12/10, 10/04/10, and 12/03/10 have also been entered.
- 2. Claims 1-4, 7-9, 13, 19, 20, 31, 32, and 48-52 are under examination.
- 3. In view of Applicant's amendments all previous rejections have been withdrawn.
- 4. The following are new grounds for rejection.
- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1-4, 7-9, 13, 19, 20, 31, 32, 48 and 50-52 are rejected under 35 U.S.C. 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. This is a written description rejection for the introduction of new matter into the claims.

The specification and the claims as originally filed do not provide support for the invention as now claimed, specifically, an antibody defined by the CDRs of SEQ ID NO:10 (light chain) and SEQ ID NO:18 (heavy chain).

Applicant cites the original claims, and pages 5-7 and 12 of the specification.

Application/Control Number: 10/583,056

Art Unit: 1644

A review of the specification reveals that SEQ ID NOs:10-17 are disclosed in Figure 4a as encoding light chain sequences. SEQ ID NOs:18 and 20-26 are disclosed in Figure 4b as encoding heavy chain sequences. It appears that the polypeptides of SEQ ID NOs:10 and 18 combine to form the 1G4 antibody V region. This is the entire disclosure regarding these polypeptides, i.e., the specification is silent regarding these polypeptides; they are only disclosed in these figures. Accordingly, the specification does not adequately describe an antibody defined only by the CDRs of the light and heavy chains of SEQ ID NOs:10 and 18, respectively.

Page 3

- 7. No claim is allowed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on (571) 272-0878.
- 9. Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/G.R. Ewoldt/
G.R. Ewoldt, Ph.D.
Primary Examiner
Technology Center 1600